 |
|
|
| |
Sustained Viral Response (SVR) Rates in Genotype 1 Treatment-naïve Patients with Chronic Hepatitis C (CHC)
Infection Treated with Vaniprevir (MK-7009), a NS3/4a
Protease Inhibitor, in Combination with Pegylated Interferon Alfa-2a and Ribavirin for 28 Days
|
| |
| |
Reported by Jules Levin
AASLD Nov 2 2010 Boston
Michael P. Manns1, Edward Gane2, Maribel Rodriguez-Torres3,
Albrecht Stoehr4, Chau-Ting Yeh5, Patrick Marcellin6, Richard
Wiedmann7, Peggy M. Hwang8, Richard J.O. Barnard9, and
Andrew W. Lee7,*
*for the MK-7009 Protocol 007 Study Group
1Medical School of Hannover, Germany, 2Auckland Clinical Studies, New Zealand, 3Fundacion de Investigacion de Diego, and Ponce School of Medicine, Puerto Rico, 4 ifi-institute for interdisciplinary medicine, Hamburg, Germany, 5Liver Research Unit, Chang Gung Medical Center, Taipei, Taiwan, 6Service d'Hepatologie, Hopital Beaujon, Clichy, France, 7 ID/Vaccines Clinical Research, 8 Biostatistics, and 9Antiviral Research, Merck Research Laboratories, North Wales and 9West
|
| |
|
|
|
|
|
